The FDA has approved Merck’s once-daily single-tablet HIV treatment Idvynso (doravirine/islatravir) for virologically suppressed adults, based on phase 3 trials showing high rates of maintained viral suppression and generally manageable safety outcomes.
$50M fuels Cleveland Clinic AI efforts, launching a "Digital Front Door" to guide patients to the right care, cut ER crowding and improve access.
A study in JAMA Dermatology found that people using an AI tool were more accurate and confident in identifying skin conditions than those using standard methods, though it did not improve their understanding of next steps for care.
The pulmonary manifestations of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is well recognized. This research fills in gaps about the prevalence and prognostic impact of interstitial lung disease in people with the autoimmune disease.
In an earning call, UnitedHealth Group executives, including CEO Stephen Hemsley, discussed the company’s strategy, which is focused value-based care, its Medicare Advantage programs transparency, AI and its transparency efforts.
Chronic low back pain develops from a mix of clinical, psychological, biological and social factors and highlights the subacute phase as a key period for early coordinated care, according to findings from a recent study.
His company has developed and is marketing a blood-based test for liver cancer that Tewarie says would outperform ultrasound scans for finding liver cancer early in people at risk for developing liver cancer.
Timely diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) could potentially reduce excess healthcare utilization and spending, according to a poster at AMCP annual meeting 2026 in Nashville.
The Pharmacy Quality Alliance recognized 10 out of 613 Medicare Part D plans for exceptional or improved medication quality based on Centers for Medicare & Medicaid Services Star Ratings.
At the AMCP Annual Meeting this week, experts from Prime Therapeutics said virtual navigation and clinical pathways are helping lower acute care use, guide treatment decisions and improve outcomes for patients with cancer.
Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains the evolution of HIV PrEP from daily oral medications to long-acting injectables and how health policy and payer strategies can improve access, adherence and outcomes.
In this interview, Luis Ortiz, M.D., explains the current and emerging therapies for narcolepsy type 1 treatment.
Evernorth’s Nicole A. Caffiero said specialty drugs dominate the pipeline, FDA approvals and the expenditures on pharmaceuticals during a keynote presentation at the AMCP annual meeting.
A CVS Caremark formulary change in May 2025 led to a short increase in patients switching GLP-1 drugs before prescribing trends leveled off, according to Truveta data presented at AMCP.
In this interview, Luis Ortiz, M.D., explains how burdensome a narcolepsy diagnosis can be for a patient and why listening to their experiences helps shape new guidelines and treatments.
Julie Kendle, Pharm.D., senior director of clinical pharmacy at IPD Analytics, explains how managed care organizations can support patients at risk of HIV.
The Maximum Fair Price (MFP), established by the Inflation Reduction Act, and the Most Favored Nation policy are reshaping how drugs are priced, paid for, and accessed.
Brian MacDonald, Pharm.D., of Prime Therapeutics discusses the low utilization of the gene therapies for hemophilia. Pfizer and BioMarin have pulled their FDA-approved hemophilia gene therapies from the market, citing low demand.
Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand.
As CAR-T therapy expands into earlier stages of treatment and new care settings, payers are weighing access, cost savings and utilization management strategies.
Data from an automated refill reminder program identified key patient behaviors and characteristics that strongly predict medication nonadherence, which could enable more targeted interventions by health plans in the future.
From 2023 to 2024, the number of uninsured people in the United States rose for the first time since 2019, mainly because pandemic-era Medicaid protections ended, eligibility checks resumed and many people could not afford or access alternative coverage, according to a new issue brief from KFF.
The anti-obesity market is now the fourth largest and is expected to grow. The pipeline contains 190 obesity-related products, IQVIA’s Scott Biggs said.
How old a person appears may offer insight into how long they live after treatment for early-stage lung cancer.
In this interview, Luis Ortiz, M.D., explains how narcolepsy type 1 is now diagnosed and how it differs from type 2.
Navitus Health Solutions saw both overall savings and reduced patient costs from the switch to the adalimumab biosimilars. Vanderbilt Health, however, experienced increased adverse events after the biosimilar conversation and further switching to other biosimilars or therapies.
Evaluating the costs and outcomes of alternative funding programs requires balancing financial objectives with patient considerations.
At the AMCP Annual Meeting, experts from Prime Therapeutics said education, policy alignment and collaboration can help improve access to precision testing while managing costs.
